$ELTP Headlines Former CEO of Elite Pharmaceut

$ELTP Headlines

Former CEO of Elite Pharmaceuticals sells all shares 10:47 a.m. Oct. 28, 2004 - James Comtois
Semel's Yahoo stock sales lead weekly insider trades 4:17 p.m. Oct. 25, 2004 - James Comtois
Elite Pharma says ends Nostrum Pharma merger talks 5:19 p.m. Aug. 6, 2004 - Carla Mozee
Elite Pharmaceuticals settles w/former CEO 12:07 p.m. May 3, 2004 - Maggie McNeil
Elite settles w/former CEO, includes $400,000 payment 1:15 p.m. April 1, 2004 - Maggie McNeil
Elite Pharma to negotiate purchase of Nostrum 2:27 p.m. Aug. 8, 2003 - Chris Kraeuter

Elite Pharmaceuticals' CEO Discusses F3Q2014 Results - Earnings Call Transcript 9:19 p.m. Feb. 18, 2014 - Seeking Alpha
10-Q: ELITE PHARMACEUTICALS INC /NV/ 9:08 a.m. Feb. 14, 2014 - Edgar Online - (EDG = 10Q, 10K)
Elite Pharmaceuticals: Swinging For The Fences 11:53 a.m. Dec. 18, 2013 - Seeking Alpha
10-K: ELITE PHARMACEUTICALS INC /NV/ 1:10 p.m. June 21, 2013 - Edgar Online - (EDG = 10Q, 10K)
1 Stock to Buy, 1 Stock to Short: Pharmaceuticals 12:01 a.m. May 10, 2013 - InvestorPlace.com
Racket of Their Own 12:01 a.m. Aug. 15, 2006 - The Wall Street Journal Interactive Edition
Bristol Nears Approval on New Drug 12:01 a.m. Sept. 4, 2002 - The Wall Street Journal Interactive Edition
Market Movers Sink in First Half 6:32 p.m. July 1, 2002 - The Wall Street Journal Interactive Edition
Arthritis War Set to Commence 1:37 a.m. Nov. 10, 1998 - The Wall Street Journal Interactive Edition

Elite Pharmaceuticals Showing Long Term Promise, Analyst Report by BrokerBank Securities, Inc. 7:30 a.m. May 5, 2014 - PR Newswire - PRF
FDA Approves Clinical Trial of BrainStorm Cell Therapeutics' ALS Treatment 10:06 a.m. April 29, 2014 - ACCESSWIRE
Elite Pharmaceuticals Granted New Patent for Abuse Deterrent Technology 7:43 a.m. April 22, 2014 - GlobeNewswire
Limitless Venture Group Settles $163,391 Note with Beaufort Capital Partners 10:08 a.m. April 16, 2014 - ACCESSWIRE
Limitless Venture Group Settles $163,391 Note with Beaufort Capital Partners 10:03 a.m. April 16, 2014 - ACCESSWIRE
Elite Pharmaceuticals to Receive up to 40 Million from Lincoln Park Capital Fund 10:02 a.m. April 15, 2014 - ACCESSWIRE
Elite Pharmaceuticals Appoints Barbara Ellison as Vice President of Quality Operations and Regulatory Affairs 12:16 p.m. March 27, 2014 - GlobeNewswire
Elite Pharmaceuticals Announces Supplemental Application for Site Transfer of Isradipine 8:05 a.m. March 24, 2014 - GlobeNewswire
Applied Materials Named a 2014 World's Most Ethical Company; KeyCorp Reported 2014 Company Run Stress Test Results and Process 12:29 a.m. March 21, 2014 - ACCESSWIRE
Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally 7:47 a.m. March 10, 2014 - GlobeNewswire
Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200 8:31 a.m. March 5, 2014 - GlobeNewswire
BlackBerry May Power Ford's Future Generation Cars 5:48 a.m. Feb. 25, 2014 - ACCESSWIRE
Forest Labs to be acquired by Actavis for $25 billion while Prana Biotech surges on drug results 1:23 a.m. Feb. 19, 2014 - ACCESSWIRE
Elite Pharmaceuticals Reports Results of Pilot Bioequivalence Study for ELI-201 8:01 a.m. Feb. 18, 2014 - GlobeNewswire
Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2014 10:50 a.m. Feb. 14, 2014 - GlobeNewswire
Elite Pharmaceuticals, Inc. to Host Third Quarter Business Update Call on February 18, 2014 4:27 p.m. Feb. 10, 2014 - GlobeNewswire
Elite Pharmaceuticals Analyst Report offers Insight and Market Data by BrokerBank Securities, Inc. 8:00 a.m. Feb. 10, 2014 - PR Newswire - PRF
TrendingWallStreet.com Releases Updates on RFMD, EZPW, GFOX, and ELTP 1:17 a.m. Jan. 30, 2014 - ACCESSWIRE
Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for Second Opioid Abuse Deterrent Product 2:22 p.m. Jan. 14, 2014 - GlobeNewswire
Elite Pharmaceuticals Initiates Pilot Bioequivalence Study for ELI-201 1:50 p.m. Dec. 5, 2013 - GlobeNewswire